🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT07784270
Starting soon Phase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270 · tracked via the Priya Life Science UK tracker
Sponsor
AstraZeneca
Phase
Phase 3
Started
2026-08-21
Last updated
2026-08-25

Condition(s) studied

Obesity or OverweightDiabetes Mellitus, Type 2

Investigational drug(s) / intervention(s)

AZD6234Placebo

AZD6234: IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

Placebo: Placebo matching IMP dose injected subcutaneously, once a week.

Study summary

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

Primary outcome measure(s)

Trial sites (218)

FacilityCityRegionStatus
Research Site Fairhope Alabama
Research Site Huntsville Alabama
Research Site Mesa Arizona
Research Site Phoenix Arizona
Research Site Tucson Arizona
Research Site Little Rock Arkansas
Research Site Bakersfield California
Research Site Gardena California
Research Site Lincoln California
Research Site Torrance California
Research Site Walnut Creek California
Research Site Coral Gables Florida
Research Site Fleming Island Florida
Research Site Fort Lauderdale Florida
Research Site Ocoee Florida
Research Site Woodstock Georgia
Research Site Chicago Illinois
Research Site Melrose Park Illinois
Research Site Lenexa Kansas
Research Site Newton Kansas
Research Site Monroe Louisiana
Research Site Beltsville Maryland
Research Site Lanham Maryland
Research Site Oxon Hill Maryland
Research Site North Dartmouth Massachusetts
Research Site Farmington Hills Michigan
Research Site Fayette Mississippi
Research Site Kansas City Missouri
Research Site St Louis Missouri
Research Site Omaha Nebraska
Research Site Omaha Nebraska
Research Site Eatontown New Jersey
Research Site Somerset New Jersey
Research Site Warren Township New Jersey
Research Site Greensboro North Carolina
Research Site Monroe North Carolina
Research Site Munroe Falls Ohio
Research Site Scottdale Pennsylvania
Research Site Franklin Tennessee
Research Site Knoxville Tennessee

+ 178 more sites — see the full list on the official registry below.

More AstraZeneca trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07784270 on ClinicalTrials.gov ↗ ← All trials in the UK